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Abstract
Neurofibromatosis (NF) is one of the most common
genetic disorders. Inherited in an autosomal dominant
fashion, this phacomatosis is classified into two geneti-
cally distinct subtypes characterized by multiple cuta-
neous lesions and tumors of the peripheral and central
nervous system. Neurofibromatosis type 1 (NF1), also
referred to as Recklinghausen's disease, affects about 1
in 3500 individuals and presents with a variety of char-
acteristic abnormalities of the skin and the peripheral
nervous system. Neurofibromatosis type 2 (NF2), pre-
viously termed central neurofibromatosis, is much
more rare occurring in less than 1 in 25 000 individu-
als. Often first clinical signs of NF2 become apparent
in the late teens with a sudden loss of hearing due to
the development of bi- or unilateral vestibular schwan-
nomas. In addition NF2 patients may suffer from fur-
ther nervous tissue tumors such as meningiomas or
gliomas. This review summarizes the characteristic fea-
tures of the two forms of NF and outlines commonal-
ities and distinctions between NF1 and NF2.
INTRODUCTION
In 1882 the German pathologist Friedrich Daniel von
Recklinghausen for the first time described a series of
patients with a combination of cutaneous lesions and
tumors of the peripheral and central nervous system.
Only in the 20th century neurofibromatosis type 1
(NF1), namely Recklinghausen's disease, and neurofi-
bromatosis type 2 (NF2), previously referred to as
central neurofibromatosis, were distinguished from
each other as two different autosomal dominantly in-
herited genetic disorders with common features [1-3].
Briefly, NF1 exposes a characteristical cutaneous phe-
notype including benign neurofibromas, which are
mixed tumors composed of all cell types found in the
peripheral nerves, hyperpigmented macules, termed
caf￩-au-lait macules, the so called axillary/inguinal
freckling, as well as pigmented hamartomas of the iris,
called Lisch nodules. NF2 on the other hand is mainly
restricted to tumors of the central and peripheral ner-
vous system, which are only seldomly accompanied by
cutaneous disorders [4].
NF1 CLINICAL FEATURES
NF1 is considered as one of the most common genet-
ic disorders in human with an incidence of 1/3500 in-
dividuals. In 1997, Gutmann and colleagues updated
the diagnostic criteria for NF1 and NF2 [5]. Usually
cutaneous manifestations are the first symptoms ob-
served in NF1 patients [6]. Caf￩-au-lait macules
(CALMs) mainly develop in childhood and are found
in almost all patients. CALMs present as light brown
macules of about 10 to 40 mm in diameter with an
ovoid shape and poorly circumscribed borders (Fig.
1). Whereas the presence of ≥ 6 CALMs is defined as
strong diagnostic criterion for NF1, additional fea-
tures are mandatory for a definite diagnosis. A com-
mon feature is a characteristic axillary and/or inguinal
freckling, which usually develops subsequently to
CALMs and which is observed in 90% of all patients
(Fig. 2) [7]. The development of neurofibromas
around or on peripheral nerves is a distinct symptom
of NF 1 but is observed to a lesser extent also in NF2
patients [1]. Neurofibromas occur as either encapsu-
lated dermal and subcutaneous tumors or as plexi-
form neurofibromas (Fig. 3). Dermal and subcuta-
neous neurofibromas may cause little or no clinical
symptoms but can be very disfiguring. Plexiform neu-
rofibromas on the other hand, which are often con-
genital and can develop near nerve roots deep within
the body, bear a 10 % probability of malignant trans-
formation. In cases of transformation the arising ma-
lignant peripheral nerve sheath tumors (MPNSTs)
have been shown to have a high metastatic potential
[2, 8-11]. Additional complications of plexiform neu-
rofibromas may manifest as diffuse appearance
and/or a tendency to expand along large segments of
affected nerves, causing disfigurement and nerve dys-
function. Finally pigmented hamartomas of the iris,
so called Lisch nodules, have to be mentioned as a
characteristic ophthalmologic feature of NF1 [9].
NF2 CLINICAL FEATURES
Whereasthe clinical features of NF2 were initially de-
scribed in the late 1800s, NF2 was first considered as a
subtype of NF1. It took almost a hundred years for
NF2 to be recognized as a self-contained entity. With
an incidence of 1/25.000 it occurs much less frequent-
ly than NF1 [1]. Often the first clinical sign of NF2 is
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bi- or unilateral vestibular schwannomas (Fig. 4) [4].
These tumors occur on or around the vestibular
branches of both auditory nerves. Unlike in NF1 pa-
tients, tumors in NF2 patients are uniformly benign.
Nevertheless, these tumors can compress associated
nerves and can cause considerable pain, nerve dys-
function and intracranial pressure. Further symptoms
include a sudden onset of tinnitus or imbalance [10].
In addition, patients suffering from NF2 tend to de-
velop further nervous tissue tumors such as menin-
giomas or gliomas. Dermal manifestations of schwan-
nomas in NF2 patients are rare and can easily be con-
fused with cutaneous neurofibromas [11]. In these cas-
es, histopathological analysis is needed to reveal that
these tumors consists of Schwann cells only. Accord-
ing to the 1991 NIH consensus criteria, the diagnosis
of NF2 requires either the presence of bilateral vesti-
bular schwannomas or a positive family history and an
unilateral vestibular schwannoma in combination with
either a menigioma, a glioma, a neurofibroma, a
schwannoma, or posterior subcapsular opacities [10].
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Fig. 1. A 9-year old boy with NF 1 and multiple (n ≥ 6) caf￩-
au-lait macules.
Fig. 2. Characteristic axillary freckling of a 51-year old
woman with NF 1.
Fig. 3a: Multiple neurofibromas with a maximum diameter of
4 cm on the back and gluteal region of a 46-year old male
with NF1. 3b: A 6 cm in diameter measuring, disabling tu-
mor in the gluteal region of a 51-year old woman with NF1.
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Inactivating mutations in the NF 1 and NF 2 genes,
both, inherited and/or new germline mutations, are
responsible for the development of the phenotypes of
the diseases. The NF1 gene, located on 17q11.2, en-
codes for a protein also known as neurofibromin.
Neurofibromin functions as a tumor suppressor by
negatively regulating mitogenic Ras signalling through
a GTPase activating protein (GAP), which is essential
for NF 1-associated tumorigenesis. Particularly in neu-
rocutaneous tissues, loss-of-function mutations result
in increased Ras activity, causing increased prolifera-
tion and tumorigenesis [1, 6, 12-14].
The NF2 gene is located on 22q12.2 and encodes
for merlin (schwannomin). The gene is much smaller
than neurofibromin, which explains the much lower
mutation rate of NF2 as compared to NF1. Merlin is
considered to act as a regulator of growth, motility,
and cellular remodeling by inhibiting the transduction
of extracellular mitogenic signals such as CD44-medi-
ated contact-dependent inhibition of proliferation.
Correspondingly, Merlin has been shown to prevent
epidermal growth factor receptor (EGFR) signalling,
known to induce cellular proliferation [1, 15, 18-20].
TREATMENT AND MANAGEMENT
Due to the variety and complexities of the manifesta-
tions of NF 1 and NF 2, an interdisciplinary approach
is inevitable. Biannual screening examinations in child-
hood and then yearly thereafter are strongly recom-
mended. Examinations should include the measure-
ment of the head circumference as well as regular
checks of blood pressure due to the risk for
pheochromocytoma and renal abnormalities [18]. In
childhood, behavioural and developmental parameters
should be evaluated carefully for signs of learning dis-
ability and attention deficit hyperactivity disorder
(ADHD) [6, 19]. In general, patients with NF 1 and
NF 2 should undergo yearly neurologic and ophthal-
mologic examinations [5]. Treatment of severe and
disfiguring tumors is usually performed by surgery.
Notably, in 2008 Lantieri and colleagues reported the
first face transplantation with a composite tissue allo-
graft in a 29-year-old man with NF1 suffering from a
massive, disfiguring plexiform neurofibroma diffusely
infiltrating the middle and lower part of his face [20].
Although benign, the complete excision of tumors of-
ten remains a therapeutical endeavour due to their
close association to nerves. It has to be noted that tu-
mor-excision bears a high risk of recurrence [1, 12].
Regarding NF2, the total surgical resection of vestibu-
lar schwannomas is a suitable therapeutic option and
may result in definite tumor control. However, due to
the frequently multilobulating and infiltrating charac-
ter of the tumors, consecutive damage to the cochlear
nerve or facial nerves is associated with a high risk of
permanent hearing loss and other malfunctions [21].
Interestingly, a recent study by Phi and colleagues
demonstrated a good 5-year tumor control and pre-
served serviceable hearing in approximately one-third
of 30 NF2 patients with vestibular schwannomas
treated with gamma knife radiosurgery [22]. Compara-
ble studies report local control rates of 85% and 81%
after 5 or 10 years, respectively, with hearing preserva-
tions of about 40%. In patients with a serviceable
hearing before therapy the estimated risk of deafness
is about 20% [10]. The authors promote radiosurgery
as an effective and less invasive treatment option com-
pared to standard surgical techniques [22]. Another
notable therapeutic approach was reported by Plotkin
and colleagues in 2008. The authors demonstrated the
first successful laboratory-to-clinic translation of re-
search by treating a 48-year-old NF2 patient with the
EGFR-inhibitor erlotinib. Application of this novel
targeted cancer drug caused a significant decrease in
tumor volume and a re-establishment of useful hear-
ing [10]. Taken together, this variety of novel and evi-
dence-based therapeutic options raises new hope for
affected patients.
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